arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Alpha Teknova, Inc.

TKNO
$8.74 ▲ +0.38 (+4.55%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
27 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Alpha Teknova, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $468.8M
Dividend Yield
Revenue Growth 18.5%
Op. Margin -23.7%
ROIC -3.8%
FCF / Share $-0.01
Trailing P/E
Price / Book 7.5x
FCF Yield
Debt / Equity 0.21
info Valuation on last close. End-of-day price, Sep 22, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$12.19M
↑ +18.5%
Net Income Profit after all expenses
$-3.17M
↑ +11.2%
Operating Margin Operating profit as % of sales
-23.7%
↑ +38.9% 6th
FCF / Share Free cash flow per share
$-0.01
↑ +83.4%
Long-Term Debt Long-term obligations
$13.22M
— +0.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
25
Financial Health
51
Cash Quality
43

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters